Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20 SEK | -5.21% | -1.96% | +29.37% |
May. 08 | Transcript : Orexo AB, Q1 2024 Earnings Call, May 08, 2024 | |
Apr. 17 | Orexo Expands, Extends US Patent for Nasal Anaphylaxis Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.37% | 65.41M | |
+15.54% | 78.51B | |
+12.05% | 9B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
+21.94% | 2.48B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B |
- Stock Market
- Equities
- ORX Stock
- News Orexo AB
- Orexo, Swedish Orphan Biovitrum to Further Explore AmorphOX Combination